Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | MAOB | P27338 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | ATM | Q13315 | 2/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | BACE1 | P56817 | 1/20 | 0.61 |
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185541 | 1.00 | MAPT (0.77) | MAPTMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL42323 | 0.87 | MAPT (1.00) | MAPTMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL10673342 | 0.87 | MAPT (1.00) | MAPTMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL3295983 | 0.87 | MAPT (1.00) | MAPTMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL820084 | 0.87 | MAPT (1.00) | MAPTMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL1404904 | 0.86 | MAPT (0.73) | MAPTMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL10612875 | 0.86 | MAPT (0.73) | MAPTMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL114330 | 0.86 | MAPT (0.73) | MAPTMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL1404905 | 0.86 | MAPT (0.73) | MAPTMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL2488973 | 0.86 | MAPT (0.73) | MAPTMAOBKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008150848-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2008-12-11 | — | — | WO | disclosed |
| US-7153849-B2 | Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans | WYETH (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060276481-A1 | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060264437-A1 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino [2,3-F]quinoline as 5-HT1A antagonists | WYETH | 2006-11-23 | — | — | US | disclosed |
| EP-1546151-B1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH CORP (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1546151-A1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | Wyeth (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6911445-B2 | For reatment of depression, childhood depression, dysthymia, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive-compulsive disorder, cocaine and alcohol addiction | WYETH (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1537121-A1 | ANTIDEPRESSANT ARYLPIPERAZINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | Wyeth (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6861427-B2 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists | WYETH (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1392697-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-F]QUINOLINE | Wyeth (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6599915-B2 | 5HT1A antagonist limit the negative feedback of autoceptors seen with serotonic reuptake inhibitors | WYETH | 2003-07-29 | — | — | US | disclosed |
| US-20030045542-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline | WYETH | 2003-03-06 | — | — | US | disclosed |
| US-20020193366-A1 | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists | WYETH | 2002-12-19 | — | — | US | disclosed |
| US-20020183322-A1 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002088130-A1 | AZABICYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-[2,3-F]QUINOLINE AS 5-HT1A ANTAGONISTS | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088132-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE AS 5-HT1AANTAGONISTS | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
| US-20020165245-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | WYETH | 2002-11-07 | — | — | US | disclosed |
| US-6458802-B1 | ANTIDEPRESSANTS, OBSESSIVE COMPULSIVE DISORDER, DIETETICS | WYETH | 2002-10-01 | — | — | US | disclosed |
| WO-2002072587-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | WYETH (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045542-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline | CYP19A1, DDT, DRD2 | MAPT 3722/4885MAOB 44/4885KMT2A 1341/4885 |
| US-20020183322-A1 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists | HTR1B, HTR1A, HTR2C | MAPT 1102/4885MAOB 36/4885KMT2A 489/4885 |
| US-20060276481-A1 | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | HTR5A, CRH, TAAR5 | MAPT 2722/4885MAOB 110/4885KMT2A 4549/4885 |
| US-20060264437-A1 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino [2,3-F]quinoline as 5-HT1A antagonists | HTR2C, HTR5A, HTR1B | MAPT 928/4885MAOB 28/4885KMT2A 509/4885 |
| US-20020165245-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | CYP19A1, DBH, DDT | MAPT 3364/4885MAOB 49/4885KMT2A 1785/4885 |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | HTR5A, CRH, CYP17A1 | MAPT 2254/4885MAOB 89/4885KMT2A 4266/4885 |
| US-20020193366-A1 | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists | HTR2C, HTR1A, HTR3B | MAPT 4148/4885MAOB 121/4885KMT2A 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.